Intelligence Profile
Science
Mechanism of Action
Cagrilintide is a long-acting synthetic analog of amylin, a hormone naturally produced by pancreatic beta cells alongside insulin. The available evidence provides insights into its molecular and physiological mechanisms, though some aspects require further investigation.
Molecular Target and Action
Cagrilintide acts as an amylin receptor agonist. Based on the cross-species research examining the dorsal vagal complex, cagrilintide appears to exert its effects on energy balance through specific neural pathways in the brainstem. The Nature Metabolism studies from 2026 identified cellular loci where cagrilintide acts and mapped neural mediators in the dorsal vagal complex that contribute to its effects on energy regulation.
Physiological Effects
The mechanism involves several physiological processes:
Glucose Regulation: As an amylin analog, cagrilintide likely slows gastric emptying and suppresses postprandial glucagon secretion, similar to native amylin. This helps regulate blood glucose levels after meals.
Energy Balance: The cross-species atlas research suggests cagrilintide influences energy balance through brainstem neural circuits, particularly in the dorsal vagal complex, which is a key region for metabolic control.
Weight Management: Clinical evidence from the REIMAGINE trials demonstrates significant effects on body weight, suggesting the compound affects appetite regulation and energy expenditure, though the precise molecular mechanisms require further elucidation.
Combined Action with GLP-1 Agonists
Much of the clinical research focuses on cagrilintide in combination with semaglutide (as CagriSema). This combination appears to provide complementary mechanisms - while semaglutide acts through GLP-1 receptors, cagrilintide works through amylin pathways, potentially offering enhanced glucose control and weight reduction compared to either agent alone.
Evidence Limitations: While the available studies provide clinical efficacy data and some neural mapping, detailed molecular pharmacology studies specifically describing cagrilintide's receptor binding kinetics, downstream signaling cascades, and tissue-specific effects are not fully detailed in the current evidence base. The mechanism of action is inferred largely from its identity as an amylin analog and the physiological effects observed in clinical trials.